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Abstract
Summary Strontium ranelate treatment is known to prevent
fractures. Here, we showed that strontium ranelate treatment
enhances bone healing and affects bone cellular activities dif-
ferently in intact and healing bone compartments: Bone for-
mation was increased only in healing compartment, while
resorption was reduced in healing and normal bone
compartments.
Introduction Systemic administration of strontium ranelate
(SrRan) accelerates the healing of bone defects; however, con-
troversy about its action on bone formation remains. We hy-
pothesize that SrRan could affect bone formation differently in
normal mature bone or in the bone healing process.
Methods Proximal tibia bone defects were created in 6-
month-old female rats, which orally received SrRan
(625 mg/kg/day, 5/7 days) or vehicle (control groups) for 4,
8, or 12 weeks. Bone samples were analyzed by micro-
computed tomography and histomorphometry in various re-
gions, i.e., metaphyseal 2nd spongiosa, a region close to the
defect, within the healing defect and in cortical defect bridging
region. Additionally, we evaluated the quality of the new bone
formed by quantitative backscattered electron imaging and by
red picosirius histology.
Results Healing of the bone defect was characterized by a
rapid onset of bone formation without cartilage formation.
Cortical defect bridging was detected earlier compared with
healing of trabecular defect. In the healing zone, SrRan stim-
ulated bone formation early and laterly decreased bone resorp-
tion improving the healing of the cortical and trabecular com-
partment without deleterious effects on bone quality. By con-
trast, in the metaphyseal compartment, SrRan only decreased
bone resorption from week 8 without any change in bone
formation, leading to little progressive increase of the
metaphyseal trabecular bone volume.
Conclusions SrRan affects bone formation differently in nor-
mal mature bone or in the bone healing process. Despite this
selective action, this led to similar increased bone volume in
both compartments without deleterious effects on the newly
bone-formed quality.
Keywords Bone defect . Bone formation . Bone healing .
Intact bone . Strontium ranelate
Introduction
Comminuted fractures, dental extraction, and trabecular or-
thopedic surgery are among the main causes mentioned lead-
ing to a local loss of bone tissue. Furthermore, long bones are
more often predisposed to osteoporotic fractures at the
metaphysis rather than at the diaphysis [1, 2]. Impaired
healing of these local cortical and trabecular bone losses af-
fects the quality of life of patients and is associated with in-
creasing health care expenditures. Due to the low inter-
fragmentary movements present at the site of these bone
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defects, the pattern of healing is usually characterized by
intramembranous bone formation without the mediation of a
cartilage template [3]. Pharmacological interventions which
could accelerate the rate of bone healing by increasing mass
as well as quality of the new bone formed are warranted.
Many drugs have been suggested to influence the processes
of bone repair [4, 5], and their effects evaluated in animals
models since this bone healing is comparable to the human
healing. However, these effects have been often studied at the
cortical level only, which is often associated to endochondral
formation.
Strontium ranelate (SrRan) treatment could be beneficial in
fracture healing [6–11]. Several case reports support a benefi-
cial effect of SrRan treatment on fracture non-union healing in
osteopenic or osteoporotic women or men [7, 8]. In preclinical
studies, SrRan treatment has been shown to promote fracture
healing by increasing callus bone formation, maturity, and
mineralization, resulting in greater callus volume with higher
biomechanical properties of the callus [9–11]. In fracture
healing, bone formation is preceded by cartilage formation
(i.e., endochondral formation) and it is not clear if SrRan treat-
ment influences cartilage formation or bone apposition or
both. Indeed, SrRan has been shown to stimulate cartilage
matrix formation and suppress collagen degradation in human
and rodent chondrocyte culture [12, 13]. However, the role of
SrRan in bone healing without cartilage template and espe-
cially in the trabecular compartment was not investigated.
We demonstrated that SrRan accelerated the filling of the
metaphyseal drill hole defect by increasing both the quantity
and the biomechanical parameters of the newly formed corti-
cal and trabecular bone [6]. A benefit of this model is that low
inter-fragmentary movements induce intramembranous bone
formation without the mediation of a cartilage template [3].
The objective is twofold: (1) to better characterize the healing
process in this bone defect and (2) to better characterize the
newly formed bone as well as to assess the cellular mechanism
related to the healing under SrRan treatment. We hypothesize
that SrRan treatment may decrease bone resorption in all com-
partments, while bone formation might be increased in the
bone healing compartment only (i.e., within the defect).
Methods
Animals and diet
All experimental designs and procedures were approved by
the Animal Ethics Committee (Authorization 1055/3574/2).
Seventy 6-month-old Sprague-Dawley female rats (Charles
River Laboratories, L’Arbresle, France) were housed individ-
ually at 25 °C with a 12:12-h light–dark cycle. The rats were
strictly pair-fed a laboratory diet containing 15% casein, 0.8%
phosphorus, 1% calcium, 70–80% carbohydrates, and 5% fat
(KLIBA-NAFAG diet 2108, Kaiseraugst, Switzerland) and
were randomly assigned to seven groups of 10 animals.
After surgery, three groups received SrRan treatment
(Servier Laboratory, Orléans, France) while the other received
the vehicle. SrRanwas administrated by gavage at a dose level
of 625 mg/kg/day, 5 days/week, which led to blood strontium
concentrations close to the level observed in human exposed
to a therapeutic dose of 2 g/day [14]. Four control groups
received 0.5% carboxymethylcellulose aqueous solution by
gavage 5 days/week since carboxymethylcellulose is used
for the encapsulation of SrRan. The volumes used in control
groups were similar to those administered in the SrRan-treated
group. The healing process was followed over time at 2, 4, 8,
and 12weeks after surgery, and at these time points, one group
of SrRan and control were euthanized by an overdose of ke-
tamine hydrochloride (except at week 2 where only 10
untreated rats were euthanized, Supl. 1.A). The control group
euthanized at week 2 was used to follow bone healing only,
while the others (treated and controls) were assessed for SrRan
treatment effects. A full description is reported in our previous
study [6].
Surgery
Animals were anesthetized with an intraperitoneal injection of
xylasine–ketamine solution (100 and 10 mg/kg, respectively).
The antero-medial part of the proximal tibia medial section of
the tibia metaphysis of both legs was exposed through an
anterior incision. A standardized drill hole defect (2.5 mm
wide and 2 mm deep) was created 1 mm below the growth
plate between the anterior tibial crest and the tendinous inser-
tion of the gracilis in the secondary spongiosa of both legs
under aseptic conditions with a dental burr under saline irri-
gation in order to avoid thermal bone necrosis. After surgery,
the skin was sutured, and a solution of buprenorphinum was
administrated (0.05 mg/kg) the day before and prior to the
surgery as well as twice a day 48 h post-surgery.
Histomorphometry
Bone labeling was performed by intraperitoneal injection of
calcein (10 mg/kg of body weight, Sigma, Buchs,
Switzerland) and tetracycline (25 mg/kg of body weight,
Sigma-Aldrich), respectively, 9 days and 1 day before eutha-
nasia. The right tibias metaphyses were embedded in methyl
methacrylate and were cut parallel to the drilling axis of the
defect (Reichert-Jung Polycut, Heidelberg, Germany). Bone
cellular parameters were evaluated with a Leica Corp. Q im-
age analyzer according to Parfitt et al. [15] (n = 6 per group).
Safranin O staining was used to assess the presence of the
cartilage template during the healing process, while red sirius
staining was used to estimate the organization and the
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diameter of collagen fibers. Indeed, large collagen fibers ap-
pear in bright red with the thinner ones in green or yellow [16,
17].
In the trabecular compartment, we assessed histological pa-
rameters in the metaphyseal compartment outside the defect area
(MC), in an area close to the defect (CDC), and in the compart-
ment at the site of the defect (DC) (Supl. 1.B). According to
standard nomenclature, cellular parameters were determined: in-
cluding osteoid surface (OS/BS, %) and thickness (O.Th, μm),
TRAcP-positive osteoclastic surfaces (Oc.S/BS, %), single- and
double-labeled surface (sLS/BS, dLS/BS, %) as well as mineral
apposition rate (MAR, μm/day). Resulting mineralizing surface
per bone surface (MS/BS, %) and bone formation rate (BFR/BS,
μm3/μm2/day) were calculated.
In the cortical compartment, O.Th and MAR were only
assessed at the endosteal level because of a large fibrin
network at the periosteal level probably related to the
healing process and/or surgery. Active osteoclastic surface
quantification was performed at endosteal and periosteal
levels and was presented as osteoclast surface per endosteal
or periosteal length.
The relative volume of fat in the marrow cavity (FV/MV,
%, n = 6 per group) was measured in the defect compartment
on Goldner staining sections using image J software. Each
input color image was split into its three-color channels. The
automated assessment of bone volume was performed on the
binary image from the red-channel image. The initial result of
the global binary thresholding was improved by image pro-
cessing (Despeckle filter) to remove noise dots. The marrow
volumewas determined asMV= total volume − bone volume.
Analysis of particles with size = 150 to 1500 pixels and cir-
cularity = 0.2 to 0.1 was performed in the region of interest of
the blue channel allowing the determination of the FV/MV,
the average adipocyte size, and number (Ad.N) per marrow
unit.
Micro-computerized tomography (μCt)
Each proximal left tibia was scanned in 0.9% NaCl solution
using μCt (μCt-40, Scanco Medical-AG, Basserdorf,
Switzerland), and data were acquired at 55 kV, 145 μA, and
207 ms integration time, with a voxel size of 20 μm allowing
the acquisition of the whole tibia metaphysis in an axis per-
pendicular to the central axis of the defect.
Corresponding zones to histological bone analysis zones
were set as the volume of interest (VOI). For the metaphyseal
compartment, VOI started from the first slice from the external
bone surface containing no cortical bone and moving dorsally
80 slices. The growth plate was carefully avoided, and a distal
strip of 1 mm height was used as VOI. For the region close to
the defect and within the healing compartment, VOI started
from the first slice from the external bone surface containing
no cortical bone and moving dorsally 40 slices. For the region
close to the defect, a strip of 1 mm height avoiding cortical
compartment and drawn around the defect was used as VOI.
In the defect compartment, a circular shape including the
whole defect was used as VOI. The segmentation parameters
were set to sigma: 0.8, support: 1, and threshold: 320, and the
same threshold was used for all compartments in order to
detect only mature bone within the defect compartment
avoiding overestimation of its filling, especially at the earlier
time point. The structural parameters of trabecular bone: bone
volume fraction (BV/TV, 1), trabecular thickness (Tb.Th,
mm), trabecular number (Tb.N, mm), trabecular separation
(Tb.Sp, mm), structure model index (SMI, 1), and connection
density (Conn.D, 1/mm) were generated from the set of pre-
viously described VOI.
Quantitative backscattered electron imaging (qBEI)
QBEI, based on the backscattered signal originating from a high
atomic number element, i.e., calcium in the bone matrix [18],
was used to determine bone mineral density distribution. QBEI
experiments were performed on the same methylmethacrylate
blocks (polished and carbon-coated) and same regions used for
histomorphometry with a scanning electron microscope (EVO
LS10, Carl Zeiss Ltd., Nanterre, France) equipped with a five
quadrant semi-conductor backscattered electron detector, as pre-
viously reported [19]. The microscope was operated at 20 kV
with a probe current of 250 pA and a working distance of 15mm
(lateral resolution 1 μm/pixel.). The backscattered signal was
calibrated using pure carbon (Z = 6, mean gray level = 25), pure
aluminum (Z = 13, mean gray level = 225), and pure silicon
(Z = 14, mean gray level = 253) standards (Micro-analysis
Consultants Ltd., St Ives, UK). As Sr might enhance the calcium
backscattered signal, the atomic surface composition was also
determined on the same region with an energy-dispersive spec-
troscopy device (Inca X-Max, Oxford Instruments, High
Wycombe, UK) fitted in the SEM. In order to accurately deter-
mine the atomic percentage of each element, a minimum of
250,000 coups were counted.
As evidenced by Beuvelot et al. [20], Sr either binds loosely
to the outer shell of the mineral or replace Ca in the hydroxy-
apatite lattice, a mean atomic number of the Sr-substituted
hydroxyapatite was calculated as follow:
Zmean ¼ ∑ Ni  Ai  Zið Þ∑ Ni  Aið Þ
Where Ni denotes the number of ith atom, Ai indicates the
atomic weight of the ith atom, and Zi represents the atomic
number of the ith atom [21].
We assumed that a pixel filled only with Sr-substituted hy-
droxyapatite would have a percentage mineralization of 100%,
whereas a pixel filled with osteoid tissue and a percentage min-
eralization of 0.02%. The calculated Zmean was used instead of
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the theoretical 14.06 Zmean of pure hydroxyapatite in the conver-
sion of gray level to mineralization percentage. Bone mineral
density distribution (Mmean: average mineral concentration) and
mineralization heterogeneity (Mwidth: width of the histogram at
half maximum of the peak) were assessed (n = 6 per group).
Statistical analysis
A sample size of 10 rats/groupwas required to detect a difference
of 10% in BV/TV within the defect (SD = 7%) between groups
and a power of 90%. Analyses were carried out using SPSS
Advanced Statistics software, and all results were expressed as
means ± SD. A two-way ANOVA with subsequent protected
least significant difference (PLSD) post hoc tests was applied
to examine the effects of time and treatment for the cortical
bridging defect compartment and for the adipocytes
histomorphometrics parameters [22]. For each trabecular bone
histomorphometric parameter, a three-way ANOVAwith subse-
quent PLSD pot hoc tests allowed the determination of the treat-
ment, time, and locations effects. The level of significance was
set at p < 0.05.
Results
Bone healing occurred without cartilage template
within the defect compartment while metaphyseal
compartment remained unaltered:
Early histologic examination at week 2 (Fig. 1a) of the control
group allowed us to more precisely describe the bone defect
healing process. The drill hole defect resulted in the disruption
of cortical bone and metaphyseal trabecular bone. Safranin or-
ange staining displayed no cartilage within the defect at week 2
orweek 4. In themetaphyseal compartment of untreated animals,
OS/BS, O.Th, MS/BS, MAR, and BFR/BS remained unaltered
over timewhile Oc.S/BS increased betweenweek 4 andweek 12
(Table 1, Fig. 2). Despite this slight increase in bone resorption,
trabecular bone micro-structural parameters remained also unal-
tered over time as well as the related architectural parameters
such as Tb.Th, Tb.N, Tb.Sp, and Conn.D (Table 2). The bone
quality at the metaphyseal compartment remained unaltered
since the mean degree of bone mineralization (Mmean) and the
heterogeneity of mineralization (Mwidth) remained unchanged
over time (Table 3).
Characterization of bone healing process in untreated rats
Formation and resorption in trabecular healing
In trabecular healing compartment of untreated rats, at week 2, a
large amount of immature bone (i.e., large volume of osteoid)
associated to a blurry calcein labeling was observed within the
trabecular defect compartment. Numerous TRAP-positive
mononuclear and multinucleated cells were present, preventing
a proper quantification of osteoclastic activities due to the pres-
ence of numerous activated macrophages involved in the local
inflammatory process (Fig. 1a). Atweek 4,moremineralized and
organized bone was observed while the tetracycline labels and
osteoid seams were clearly observed, indicating that the bone
formed slower as compared to week 2. At week 2 and week 4,
histologic examination showed that bone formation initiated in
the area at the periphery of the trabecular bone defect on the
nearby endocortical surface. From week 4, OS/BS, MS/BS,
and BFR/BS were nearly twice higher in the trabecular defect
compartment as compared to metaphyseal compartment and
remained unchanged over time (Table 1, Fig. 2). Trabecular bone
resorption increased with time and was higher at week 8 and
week 12 as compared to bone resorption in the metaphyseal
compartment at the same time point (Fig. 2).
Formation and resorption in cortical healing
O.Th remained unchanged over time, while MAR progres-
sively decreased between week 4 and week 12 (Table 4). At
endosteal level, osteoclast surface per endosteal length rapidly
decreased between week 4 and week 8 and stabilized thereaf-
ter. At the periosteal level, osteoclast surfaces per periosteal
length was first threefold increased at week 8 as compared to
week 4 and was then decreased at week 12 as compared to
week 8 and normalized as compared to week 4 (Table 4).
Consequences of bone cellular activity modulations related
to healing on newly formed bone tissue
Cortical bone morphometric parameters were evaluated in the
previous work conducted by Zacchetti et al. [6], while new
trabecular regions of interest which match with histologic as-
sessment were analyzed. For information, cortical thickness
progressively increased over time: The cortical bone bridging
the defect was fully repaired at week 12 [6]. In the trabecular
compartment of the defect, BV/TV was decreased between
week 2 and 8 (−45%, p < 0.0005 at week 4 and −75%,
p < 0.0005 at week 8) and remained relatively constant until
week 12 (Fig. 1b and Table 2). In the control group, at week 4,
large collagen fibers had already appeared in bright red and
were predominant at the cortical and trabecular compartments
of the healing zone on red picosirius-stained sections (Supl.2).
Within the defect, the mean degree of bone mineralization
(Mmean) was approximately 10% lower at week 4 as com-
pared to the two other trabecular compartments (p = .002 for
both) but increased with time and finally normalized at week
12 (Table 3). The heterogeneity of mineralization (Mwidth)
decreased with time within the defect compartment and be-
came lower compared to the metaphyseal compartment. At
the cortical level within the defect, the mean degree of bone
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mineralization increased between week 4 and 12 while the
heterogeneity of mineralization decreased.
SrRan treatment effects
Sr incorporation within the different trabecular and cortical
compartments
In control groups, and at trabecular level, the Sr/Ca ratio
remained constant over time and in all compartments ana-
lyzed (Table 3.). In SrRan-treated groups, the Sr/Ca ratio
increased over time between week 4 and 12 in the
metaphyseal compartment but remained constant in the re-
gion close to the defect and within the healing compart-
ment. However, Sr/Ca ratio was higher in all compartments
analyzed and at each time point as compared to time and
compartment-matched control group. The magnitude of this
gain was more pronounced in the healing zone (more than
threefold) as compared to the metaphyseal compartment
and to the region close to the defect (around twofold in-
creased). At the cortical level of the bone bridging the
defect, the Sr/Ca ratio was also fourfold higher in SrRan-
treated groups than in controls and remained unaltered over
time of treatment.
Fig. 1 Characterization of the
healing process: a Representative
histologic sections of the defect
compartment at week 2. Top left:
Safranin orange staining. Top
right: Double-calcein labeling
under UV lightening, Bottom left:
Trap staining, Bottom right:
Goldner staining. Two weeks
after the creation of the bone
defect, the blurry calcein labelling
indicates an intense bone
formation without any cartilage
callus formation observed by the
safranin orange staining section.
Instead, immature bone was
observed with a large volume of
osteoid associated to the presence
of numerous TRAP-positive
mononuclear cells and
multinucleated at the vicinity of
the bone or within the bone
marrow. bModulation of
trabecular bone volume within the
healing compartment in the
control group. Trabecular bone
volume (BV/TV) assessed by
microcomputed tomography
suggested an early bone accretion
followed by bone resorption. Data
are presented as mean ± SE. t2:
p < 0.05, compared toweek 2; (t4)
p = 0.082, compared to week 4
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Effects of SrRan in the metaphyseal compartment
SrRan treatment had no effect on bone formation in the
metaphyseal compartment: OS/BS, O.Th, MS/BS, MAR, and
BFR/BS remained unaltered by treatment and also over time
(Table 1 and Fig. 2b). In SrRan-treated groups, bone resorption
first decreased between week 4 and week 8 and then increased
until week 12 but Oc.S/BS was lower at each time point evalu-
ated as compared to respective controls (Fig. 2a). At the tissue
level, and in contrast to the control rats, BV/TV was increased at
week 8 and 12 after SrRan treatment compared to week 4 in the
metaphyseal compartment (respectively +25%, p = .050 and
+35%, p = .009). The time-related increased BV/TV was asso-
ciated with a progressive increase of Tb.Th fromweek 4 to week
12 (+14%, p = .050 and 18%, p < 0.0005, respectively).
Therefore, in the metaphyseal compartment, SrRan treatment
induced a higher BV/TV at week 8 and 12 as compared to re-
spective controls (respectively +53%, p < 0.0005 and +35%,
p = .022). This was mainly associated to higher Tb.Th in
SrRan-treated rats as compared to control rats at these time
points. Worth noting at week 8 is that Tb.Sp was also decreased,
while Tb.Th, Tb.N, and Conn.Dwere increased in SrRan-treated
animals as compared to controls.
Effects of SrRan in the healing compartment
Similarly as in the metaphyseal compartment, no evident effects
of SrRan treatment have been identified in the healing trabecular
bone at any time point evaluated for OS/BS and O.Th parame-
ters (Fig. 2 and Tr x L > .05 in Table 5). In contrast, in the
healing compartment only, SrRan treatment led to higher MS/
BS and MAR within the defect at week 4 (respectively +47%,
p < 0.0005 and +16%, p = .046, Tr x L < .05 in Table 5) as
compared to time-matched controls and to a trend of increase for
MS/BS at week 8 (+22%, p = .067). This led to higher BFR/BS
at week 4 and 8 in the healing compartment of SrRan-treated
groups as compared to time and compartment-matched controls
(respectively +70.5%, p < 0.0005 and +35.5%, p = .029 in Fig. 2
and Tr x L < .05 in Table 5). These parameters progressively
decreased from week 4 to week 12 and reached similar value as
Table 1 Effects of SrRan treatment in the three trabecular compartments
Metaphyseal compartment Around the defect Defect compartment
Ctrl SrRan Ctrl SrRan Ctrl zSrRan
Week 4
OS/BS (%) 16.93 ± 5.43 13.87 ± 4.34 12.52 ± 2.75 10.66 ± 1.98 29.38 ± 14.23 lm,c 27.66 ± 7.80 lm,c
O.Th (μm) 2.0 ± 0.3 2.2 ± 0.3 1.9 ± 0.3 2.2 ± 0.3 2.1 ± 0.6 2.5 ± 0.6
FV/MV(%) NA NA NA NA 18.61 ± 3.38 17.49 ± 3.39
Adipocyte size (pixel) NA NA NA NA 413.375 ± 30.441 422.500 ± 46.558
Ad.N/marrow unit (1/pixel2) NA NA NA NA 4.50E-04 ± 2.90E-05 4.10E-04 ± 2.00E-05
Week 8
OS/BS (%) 14.78 ± 7.70 12.96 ± 6.73 10.26 ± 3.62 8.99 ± 2.50 22.42 ± 13.11 lm,c 25.51 ± 5.56 lm,c
O.Th (μm) 1.9 ± 0.4 2.0 ± 0.3 1.8 ± 0.2 1.9 ± 0.4 1.8 ± 0.4 1.8 ± 0.2 t4
FV/MV(%) NA NA NA NA 19.01 ± 3.97 20.28 ± 3.32
Adipocyte size (pixel) NA NA NA NA 416.375 ± 56.215 444.667 ± 57.872
Ad.N/marrow unit (1/pixel2) NA NA NA NA 4.60E-04 ± 3.30E-05 4.60E-04 ± 2.40E-05
Week 12
OS/BS (%) 12.39 ± 3.42 12.98 ± 7.36 12.11 ± 3.69 8.56 ± 3.03 29.53 ± 10.45 lm,c 21.43 ± 11.09 lm,c
O.Th (μm) 1.9 ± 0.2 2.1 ± 0.3 1.93 ± 0.25 2.00 ± 0.28 t4 1.9 ± 0.4 2.1 ± 0.2 (t4)
FV/MV(%) NA NA NA NA 17.06 ± 4.44 19.62 ± 4.71
Adipocyte size (pixel) NA NA NA NA 386.500 ± 41.932 414.071 ± 37.495
Ad.N/marrow unit (1/pixel2) NA NA NA NA 4.40E-04 ± 3.50E-05 4.70E-04 ± 3.50E-05
Location effect: Time effect: Treatment effect:
lm: p < 0.05, compared to MC
Compared to control treatment and time-matched
group
t4: p < 0.05, compared to week 4
treatment and compartment-matched
group.
*: p < 0.05, time and compartment-matched
group.
NA: Not assessed
lc: p < 0.05, compared to CDC
treatment and time-matched group.
t8: p < 0.05, compared to week 8
treatment and compartment-matched
group.
MC metaphyseal compartment, CDC close to the defect compartment
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compared to the compartment-matched control at week 12.
SrRan administration did not affect FM/MV, average adipocyte
size, or adipocyte number per marrow unit at any time point of
treatment in the healing compartment (Table 1). Similarly as in
the metaphyseal compartment, in SrRan-treated groups, bone
resorption first decreased between week 4 and week 8 and then
increased until week 12. This led to approximately 30–35%
lower Oc.S/BS at week 8 and 12 in SrRan-treated groups in
each compartment as compared to respective controls (Fig.
2a). At the earliest time point (week 4), in the metaphyseal
compartment, SrRan treatment induced a decrease of Oc.S/BS
(−15%, p = .025). In contrast, bone resorption was increased
within the healing zone in SrRan-treated rats (+27%,
p = .008). Similarly as in the metaphyseal compartment, in the
healing compartment, SrRan treatment increased BV/TV at
week 8 and 12 (only a trend at week 8, respectively +149%,
p = .062 and +227%, p = .001, Tr x L > .05 in Table 5) as
compared to controls as well as higher Tb.Th and Conn.D.
Fig. 2 Effects of SrRan on bone
resorption (a) and formation (b)
within the three different
trabecular compartments. In the
trabecular compartment of the
healing zone, SrRan stimulated
formation and resorption at week
4. Bone formation then decreased
over time and normalized at week
12, while bone resorption
decreased and became lower as
compared to the controls at weeks
8 and 12. By contrast, in the
metaphyseal compartment, SrRan
only decreased bone resorption
from week 8 without any bone
formation alterations. The
compartment close to the defect is
characterized by a transient state
between other compartment. Data
are presented as Mean ± SE. MC:
Metaphyseal compartment, CDC:
close to the defect compartment
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At cortical level, endosteal O.Th decreased with the time of
treatment in SrRan group but remained similar to controls.
Endosteal MAR tended to be higher (45%) at week 4 com-
pared to control and rapidly decreased to reach equivalent
value as control rats at week 8 and week 12 (Tables 4 and
5). At the endosteal level, osteoclast surface per endosteal
length was not affected by treatment. At periosteal level, sim-
ilar to the controls, resorption was transiently increased at
week 8 but with a lower magnitude compared to that in the
time matched control group (−50% but not significantly,
p = .082).
Consequences of bone cellular activity modulations related
to healing and SrRan treatment on newly formed bone tissue
At the trabecular and cortical defect compartments, colla-
gen thickness, and/or organization as well as the mean
degree and the heterogeneity of bone mineralization did
not differ between vehicle and SRan-treated group.
Similarly to controls, at the cortical level within the defect,
the mean degree of bone mineralization increased between
week 4 and 12 but to a lower extent in the SrRan-treated
groups (p = .019). This led to a slightly lower mean degree
of bone mineralization at week 12 in SrRan-treated group
as compared to control (−7%, p = .019). In contrast, the
heterogeneity of mineralization decreased with time in
both control and treated groups between week 4 and 12,
but heterogeneity in SrRan treated rats was lower at week 4
as compared to controls (−13%, p = .025).
Effects of SrRan in the compartment close to the defect
In the region close to the defect, MS/BS was higher or
tended to be higher in SrRan-treated rats as compared to
Table 2 Effects of SrRan treatment on trabecular bone morphometric parameters assessed by micro-computerized tomography
Metaphyseal compartment Around the defect Defect compartment
Ctrl SrRan Ctrl SrRan Ctrl SrRan
Week 4
TV (mm3) 5.10 ± 0.26 4.94 ± 0.27 1.66 ± 0.06 1.70 ± 0.16 3.15 ± 0.17 3.26 ± 0.13
BV/TV (1) 0.33 ± 0.11 0.34 ± 0.09 0.33 ± 0.07 0.38 ± 0.07 0.09 ± 0.07 lm,c 0.13 ± 0.07 lm,c
Conn.D (1/mm3) 132.1 ± 42.6 142.2 ± 42.7 86.8 ± 18.3 lm 96.4 ± 22.5 lm 39.7 ± 37.8 lm,c 56.4 ± 36.5 lm,c
Tb_N (1/mm) 5.44 ± 0.81 5.57 ± 0.85 4.86 ± 0.57 lm 5.10 ± 0.56 3.35 ± 0.57 lm,c 3.32 ± 0.45 lm,c
Tb.Th (mm) 0.081 ± 0.011 0.080 ± 0.007 0.092 ± 0.009 lm 0.097 ± 0.009 lm 0.062 ± 0.011 lm,c 0.070 ± 0.009 lm,c
Tb.Sp (mm) 0.17 ± 0.04 0.17 ± 0.04 0.19 ± 0.03 0.17 ± 0.02 0.32 ± 0.05 lm,c 0.33 ± 0.04 lm,c
Week 8
TV (mm3) 4.35 ± 0.33 4.41 ± 0.3 1.65 ± 0.47 1.64 ± 0.08 2.82 ± 0.11 2.96 ± 0.18
BV/TV (1) 0.27 ± 0.07 0.42 ± 0.05 t4 * 0.25 ± 0.06 t4 0.38 ± 0.08 * 0.04 ± 0.06 lm,c 0.10 ± 0.08 lm,c (*)
Conn.D (1/mm3) 106.5 ± 39.1 151.6 ± 20.5 * 72.9 ± 23.8 lm 110.6 ± 25.2 lm * 13.8 ± 27.1 lm,c (t4) 34.1 ± 28.1 lm,c *
Tb_N (1/mm) 4.84 ± 0.81 5.94 ± 0.43 * 4.46 ± 0.57 5.35 ± 0.74 lm * 2.92 ± 0.79 lm,c 3.10 ± 0.53 lm,c
Tb.Th (mm) 0.077 ± 0.009 0.088 ± 0.005 t4 * 0.080 ± 0.012 t4 0.094 ± 0.008 * 0.053 ± 0.011 lm,c (t4) 0.069 ± 0.014 lm,c *
Tb.Sp (mm) 0.20 ± 0.04 0.14 ± 0.02 * 0.22 ± 0.04 (t4) 0.17 ± 0.04 * 0.39 ± 0.08 lm,c (t4) 0.35 ± 0.05 lm,c
Week 12
TV (mm3) 4.93 ± 0.26 5.22 ± 0.51 1.62 ± 0.75 1.51 ± 0.13 2.96 ± 0.21 2.88 ± 0.19
BV/TV (1) 0.34 ± 0.09 0.45 ± 0.12 t4 * 0.30 ± 0.07 0.43 ± 0.09 * 0.05 ± 0.03 lm,c 0.17 ± 0.08 lm,c *
Conn.D (1/mm3) 129.5 ± 36.6 139.4 ± 27.2 85.1 ± 25.7 lm 126.8 ± 24.0 t4 * 12.6 ± 9.8 lm,c (t4) 61.1 ± 38.4 lm,c *
Tb_N (1/mm) 5.45 ± 0.84 6.00 ± 0.86 4.80 ± 0.66 lm 5.65 ± 0.55 * 2.95 ± 0.29 lm,c 3.42 ± 0.80 lm,c
Tb.Th (mm) 0.083 ± 0.00 0.098 ± 0.011 t4,8 * 0.087 ± 0.009 0.097 ± 0.011 * 0.062 ± 0.010 lm,c 0.078 ± 0.011 lm,c *
Tb.Sp (mm) 0.17 ± 0.04 0.15 ± 0.03 0.19 ± 0.03 0.15 ± 0.02 * 0.35 ± 0.03 lm,c 0.34 ± 0.09 lm,c
Location effect: Time effect: Treatment effect:
lm: p < 0.05, compared to MC
Compared to control treatment and time-matched
group
t4: p < 0.05, compared to week 4
treatment and compartment-matched
group.
*: p < 0.05, time and compartment-matched
group.
lc: p < 0.05, compared to CDC
treatment and time-matched group.
t8: p < 0.05, compared to week 8
treatment and compartment-matched
group.
MC metaphyseal compartment, CDC close to the defect compartment
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respective control at weeks 4 and 8 (+54%, p = .008 and
+36%, p = .097 respectively; Fig. 2). MAR was unaltered
by treatment leading to higher BFR/BS at week 4 and
week 8 in SrRan vs time and compartment-matched con-
trol group (respectively +47%, p = .033 and +43%,
p = .016; Fig. 2). While BFR/BS remained unaltered over
the time in controls, in SrRan-treated rats, it declined from
week 4 to 8 and normalized at week 8 as compared to
controls. However, the magnitude of this early increase
bone formation as compared to controls was less
Table 3 Strontium incorporation and degree of mineralization in the three trabecular compartments (A) and in cortices within the defect compartment
(B)
A Metaphyseal compartment Around the defect Defect compartment
Ctrl SrRan Ctrl SrRan Ctrl SrRan
Week 4
Sr/Ca (% atomic) 0.010 ± 0.004 0.015 ± 0.003 * 0.008 ± 0.001 0.018 ± 0.005 * 0.012 ± 0.005 0.036 ± 0.006 lm,c *
Mmean 54.0 ± 1.7 57.0 ± 2.5 54.9 ± 2.1 57.0 ± 2.2 49.0 ± 3.4 lm,c 51.2 ± 3.2 lm,c
Mwidth 8.96 ± 0.83 8.79 ± 1.34 7.92 ± 0.41 8.03 ± 0.72 8.94 ± 1.73 9.73 ± 1.47
Week 12
Sr/Ca (% atomic) 0.009 ± 0.003 0.025 ± 0.004 t4 * 0.010 ± 0.002 0.019 ± 0.004 lm * 0.008 ± 0.003 0.033 ± 0.003 lm,c *
Mmean 56.9 ± 3.8 55.9 ± 2.0 57.1 ± 3.5 56.3 ± 2.7 56.6 ± 3.1 t4 53.8 ± 2.5 t4
Mwidth 9.51 ± 1.10 9.93 ± 0.91 7.73 ± 0.49 lm 8.55 ± 1.19 lm 7.21 ± 0.51 lm t4 7.98 ± 0.79 lm t4
B Week 4 Week 12
Ctrl SrRan Ctrl SrRan
Sr/Ca (% atomic) 0.008 ± 0.002 0.038 ± 0.005 * 0.008 ± 0.001 0.038 ± 0.004 *
Mmean 49.5 ± 3.1 47.9 ± 2.9 56.4 ± 2.9 t4 52.2 ± 2.3 t4 *
Mwidth 10.35 ± 0.92 9.01 ± 0.84 * 6.67 ± 0.42 t4 7.07 ± 0.81 t4
Location effect: Time effect: Treatment effect:
lm: p < 0.05, compared to MC
Compared to control treatment and time-matched
group
t4: p < 0.05, compared to week 4
treatment and compartment-matched
group.
*: p < 0.05, time and compartment-matched
group.
lc: p < 0.05, compared to CDC
treatment and time-matched group.
t8: p < 0.05, compared to week 8
treatment and compartment-matched
group.
MC metaphyseal compartment, CDC close to the defect compartment
Table 4 Effects of SrRan treatment on cortical bone parameters in the defect compartment
Week 4 Week 8 Week 12
Ctrl SrRan Ctrl SrRan Ctrl SrRan
Endosteal O.Th (μm) 3.82 ± 1.81 4.27 ± 0.88 4.08 ± 1.57 3.37 ± 0.83 t4 2.82 ± 0.67 2.98 ± 0.70 t4
Endosteal MAR (μm/d) 2.5 ± 0.3 3.7 ± 1.0 * 2.2 ± 0.6 2.3 ± 0.4 t4 1.8 ± 0.2 t4 1.6 ± 0.3 t4
Periosteal Oc.S per periosteal length (%) 3.82 ± 2.90 6.52 ± 8.51 13.69 ± 7.71 t4 7.06 ± 5.73 t4 (*) 5.75 ± 3.94 t8 5.17 ± 5.86 t8
Endosteal Oc.S per endosteal length (%) 10.96 ± 7.57 6.63 ± 4.87 1.17 ± 1.22 t4 1.04 ± 0.66 t4 1.17 ± 1.56 t4 1.58 ± 1.23 t8
Location effect: Time effect: Treatment effect:
lm: p < 0.05, compared to MC
Compared to control treatment and time-matched
group
t4: p < 0.05, compared to week 4
treatment and compartment-matched
group.
*: p < 0.05, time and compartment-matched
group.
lc: p < 0.05, compared to CDC
treatment and time-matched group.
t8: p < 0.05, compared to week 8
treatment and compartment-matched
group.
MC: Metaphyseal compartment, CDC: close to the defect compartment
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significant in the region close to the defect as compared to
within the healing zone. At the earliest time point (week
4), in the metaphyseal compartment, SrRan treatment in-
duced a decrease of Oc.S/BS (−15%, p = .025, Fig. 2)
while Oc.S/BS remained unaltered in the region close to
the defect. In contrast, bone resorption was increased
within the healing zone in SrRan-treated rats (+27%,
p = .008).
At the tissue level (Table 2), and in contrast to the con-
trol rats, BV/TV was increased at week 8 and 12 after
SrRan treatment compared to week 4 in the metaphyseal
compartment (respectively +25%, p = .050 and +35%,
p = .009) but it was non-altered with time in the region
close to the defect, and within the healing compartment.
As compared to controls, SrRan treatment decreased Tb.Sp
and increased Tb.Th, Tb.N, and Conn.D at both weeks 8
and 12, leading to higher BV/TV (+54%, p < 0.0005 and
+43%, p < 0.0005 respectively). At the trabecular level, the
mean degree of bone mineralization (Mmean) was similar
in metaphyseal and close to the defect compartment and
was unaltered over time (Table 3).
Discussion
We first characterized the healing process in this bone defect
and then evaluated whether SrRan could differently influence
bone cellular activities in healing or in intact bone.
At the early phase of defect healing, woven bone is being laid
down in the defect as an initial healing response without cartilage
formation at week 2. Since endochondral ossification occurs
within the first 3 weeks in rats [23, 24], we can conclude that
healing occurred through intramembranous-like bone formation
in this model. Within the defect, trabecular bone volume de-
creased rapidly between weeks 2 and 8 and remained relatively
constant until week 12, as shown in similar models such as
epimetaphyseal defects or bone marrow ablation [25, 26].
Interestingly, the pattern of bone cellular activities over time
within the defect of control animals is similar as during growth
since bone formation overcomes bone resorption, while after the
peak of bone volume acquisition bone turnover continues at a
slower rate with the predominance of bone resorption over bone
formation [27]. The intense bone formation activities during the
first 2 weeks could result from increased availability of
Table 5 Overview of main
effects from statistical analysis Main effects and interactions
Tr Ti L Tr x Ti Tr x L Ti x L Tr x Ti x L
OS/BS .060 .076 .000 .400 .981 .874 .290
O.Th .005 .002 .360 .339 .917 .538 .913
FV/MV .418 .453 NA .393 NA NA NA
Adipocyte Size .108 .188 NA .797 NA NA NA
Ad.N/marrow unit (1/pixel2) .811 .512 NA .563 NA NA NA
Oc.S/BS .000 .000 .000 .000 .046 .001 .004
MS/BS .000 .000 .000 .000 .085 .000 .152
MAR .199 .000 .000 .444 .019 .925 .625
BFR/BS .000 .000 .000 .000 .002 .000 .000
Endosteal O.Th .925 .024 NA .366 NA NA NA
Endosteal MAR .070 .000 NA .010 NA NA NA
Periosteal Oc.S per periosteal length (%) .249 .055 NA .260 NA NA NA
Endosteal Oc.S per endosteal length (%) .303 .000 NA .279 NA NA NA
BV/TV .000 .006 .000 .002 .590 .331 .565
Conn.D .000 .090 .000 .085 .750 .312 .234
Tb_N .000 .078 .000 .029 .150 .708 .650
Tb.Th .000 .001 .000 .011 .425 .055 .830
Tb.Sp .000 .020 .000 .041 .520 .334 .984
Trabecular Sr/Ca .000 .551 .000 .039 .000 .005 .021
Trabecular Mmean .551 .001 .000 .005 .711 .013 .804
Trabecular Mwidth .068 .315 .000 .381 .558 .000 .807
Cortical Sr/Ca .000 .816 NA .816 NA NA NA
Cortical Mmean .021 .000 NA .269 NA NA NA
Cortical Mwidth .150 .000 NA .012 NA NA NA
Italicized items are significant results
Tr treatment effect, Ti time effect, L location effect, NA not assessed
Osteoporos Int
mesenchymal stem cell within the defect [28]. Significant vascu-
larization within the defect could promote the osteoclastic pro-
genitors and enhance progressively bone resorption as already
described in bone marrow ablation model [29].
Metaphyseal compartment seemed uninfluenced by healing
since in control animals, bone cellular activities remained rela-
tively constant and were lower as compared to the healing com-
partment. While formation remained unaltered over time, resorp-
tion only slightly increased and could be attributed to normal
increased resorption related to aging and therefore to normal
bone remodeling. Under SrRan treatment, bone formation
remained unaltered but resorption was decreased from week 8,
leading to the progressive increase of the trabecular bone volume
progressively with time of treatment. Accordingly, SrRan is only
maintained but not further stimulated the bone formation, while
resorption was reduced is in accordance with clinical studies
[19–21] and preclinical studies [22–24] using mature animals.
In osteoporotic patients, the effects of SrRan treatment on bone
cell activities were modest without a stimulation of bone forma-
tion or a significant decline of bone resorption [30, 31].
In the healing compartment, we showed that SrRan alters
bone cellular activities differently as in the metaphyseal compart-
ment but led to similar increased trabecular bone volume. In the
early phase of defect healing (woven bone formation), SrRan
treatment induced a higher bone turnover as in controls. Bone
formation rate was 60% higher (week 4) as compared to controls
and then progressively declined over time as remodeling of the
woven bone occurred. Accordingly, Fournier et al. and Peng
et al. [32, 33] also showed that SrRan administration in respec-
tively 3-month-old mice or rats (i.e., growing) lowered bone
marrow adiposity and increased trabecular bone volume in prox-
imal tibia metaphysis by driving the commitment of multipotent
mesenchymal stem cells into osteoblast rather than in adipocyte
lineage. In our model, no differences were observed in marrow
fat volume within the defect and we hypothesize that SrRan
treatment preferentially affected the apposition and even more
the mineralization function of the osteoblast rather than their
number (as MS/BS and MAR were altered by SrRan treatment,
but not OS/BS). In the early phase of defect healing, the trabec-
ular bone resorption of the SrRan-treated groups was transitorily
higher. Accordingly, in a rat tibial metaphyseal bone defect mod-
el, Komrakova et al. [34] showed an increased expression of
TRAP gene and a lower OPG/Rankl ratio after 5 weeks of
SrRan treatment. Then, as the newly formed bone is remodeled,
bone resorption decreased and became lower in SrRan-treated
groups. By lowering bone resorption, bisphosphonate treatment
is known to delay the remodeling from primary woven bone to
lamellar bone [35]. In thismodel, themild reduction of resorption
did not seem to influence bone quality of the newly formed bone
(see below) and did not delay in the resolution of the defect.
Congruently, bone cellular alterations related to SrRan treatment
within the defect are in agreement with previous findings in
growing animals: SrRan treatment was associated to a positive
bone balance with plausible increased bone formation [25, 26].
Despite no human available data about SrRan effects during
growth, Stathopoulos et al. [36] have shown in a case report that
SrRan improves delayed healing of osteolytic lesions of the jaw
by a decreased osteoclastic activity as well as potential enhance-
ment of osteoblastogenesis.
Despite SrRan improved cortical and trabecular bone micro-
architecture in healing compartment, the associated increased
bone turnover rate occurring in the earlier weeks of healing could
lead to inadequate secondary mineralization of the bone matrix
and could alter its quality. However, SrRan treatment preserved
the structural network of collagen fibers as well as the degree and
the heterogeneity of bone mineralization at the trabecular com-
partment. These results are in accordance with other studies per-
formed in animal and human bone specimens [37, 38]. At the
cortical level, SrRan treatment first not only reduced the hetero-
geneity of mineralization at week 4 but also decreased mean
mineralization at week 12. Since cortical healing occurred faster
as compared to the trabecular compartment, secondary mineral-
ization of the bone matrix could be more altered. However, in
this model, Zacchetti et al. [6] did not show any alterations of the
cortical material level properties at week 12, indicating that other
parameters related to bone quality were improved, such as phys-
icochemical effect associated to SrRan [39].
In the compartment close to the defect, we observed tran-
sient effects of SrRan (at the cellular and tissue levels) as com-
pared to the metaphyseal compartment and healing zone. This
could be related to the diffusion of growth factors from the
healing zone which could diffuse into the surrounding area of
the defect. Indeed, the higher bone turnover induced by SrRan
treatment in the compartment close to the defect in the early
phase of healing could be associated with the release of SrRan-
induced soluble factors. Among them, IGF-I action is known to
be particularly valuable during bone growth and consolidation,
and its expression has been shown to be transiently expressed in
the first 4 weeks of bone healing occurring by intramembranous
ossification [40]. Interestingly, in growing rats, Brennan et al.
have also shown that IGF-I expression was increased in the
bone after 2 and 4 weeks of SrRan treatment [41]. Further,
similarly to our model, overexpression of IGF-I in cells of the
osteoblast lineage increased indices of bone formation and re-
sorption [42] and lead to increased late osteoblast function such
as the process of mineral apposition [43]. On the other hand,
osteogenesis and angiogenesis are tightly related during bone
growth, remodeling, and repair [44] and vascular endothelial
growth factor (VEGF) was found to stimulate bone healing
through intramembranous ossification [45, 46]. Since SrRan-
doped calcium scaffold stimulated the release of VEGF in vitro
and in vivo models [47, 48], SrRan could stimulate angiogen-
esis in the defect compartment and enhance bone formation. By
increasing vascularization within the defect, this could also lead
to an increase in the osteoclast progenitor availability within the
defect and therefore increase Oc.S/BS in SrRan-treated groups
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at the early phase of healing (week 4). Finally, due to the higher
bone turnover rate within the healing compartment, the Sr/Ca
ratio was higher as compared to others compartments [49] and
could be more biologically available.
Conclusion
In the trabecular healing zone, SrRan stimulated formation and
resorption early. Then, as the newly formed bone is remodeled,
bone formation normalized while bone resorption was reduced
under SrRan treatment. By contrast, in the metaphyseal com-
partment, SrRan decreased bone resorption without any change
in bone formation. Despite the selective action of SrRan on
bone formation, this led to a comparable increase in trabecular
bone volume in both compartments without deleterious effects
on the quality of newly formed bone. In the cortical healing
zone, srRan accelerated the growth of cortical bone over the
defect. This was mainly related to an early increase of endosteal
formation but led to a slight impairment of secondary mineral-
ization of the newly formed bone matrix.
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